Frontiers in HIV Pathogenesis, Therapy and Eradication

HIV发病机制、治疗和根除的前沿

• 批准号: 8260640
• 负责人: James Wavell Aiken
• 金额: $ 2万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-01-09 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8260640
• 关键词: AIDS/HIV problem; Academia; Acquired Immunodeficiency Syndrome; Address; Antiviral Therapy; Area; Arts; Biology; Biology of HIV Infection; British Columbia; Canada; Cells; Cellular biology; Cessation of life; Chronic Hepatitis; Collaborations; Communication; Communication Research; Drug Formulations; Drug resistance; Educational workshop; Environment; Exposure to; Fostering; Gene Expression; HIV; HIV-1; Highly Active Antiretroviral Therapy; Industry; International; Joints; Knowledge; Maintenance; Mentors; Methodology; Outcome; Pathogenesis; Patients; Pharmacology; Private Sector; Request for Applications; Research; Research Personnel; Science; Scientist; Study models; Training; Viral; Viral hepatitis; Virus; abstracting; clinical practice; drug development; experience; frontier; inhibitor/antagonist; interest; latent infection; meetings; novel; pandemic disease; resistant strain; symposium; virus host interaction

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled Frontiers in HIV Pathogenesis, Therapy and Eradication, organized by Alan N. Engelman, Eric O. Freed and John M. Coffin, which will be held in Whistler, British Columbia, Canada from March 26-31, 2012. AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology, and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors, and important virus-host interactions. Speakers selected from submitted abstracts will fill-out workshops on pharmacological approaches and the cell biology of HIV infection. PUBLIC HEALTH RELEVANCE: The 2012 Keystone Symposium on Frontiers in HIV Pathogenesis, Therapy and Eradication will address key issues related to the control of the global HIV/AIDS pandemic including potential eradication of persistent viral reservoir(s) from patients. Considering that UNAIDS estimated 1.8 million AIDS-related deaths in 2009, the meeting is both timely and highly significant. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis, which will share a keynote address and two plenary sessions with this meeting.

描述： 本申请请求支持题为“艾滋病毒发病机制、治疗和根除前沿”的 Keystone 研讨会，该会议由 Alan N. Engelman、Eric O. Freed 和 John M. Coffin 组织，将于 3 月 26 日在加拿大不列颠哥伦比亚省惠斯勒举行2012年-31日。艾滋病无法治愈，因为潜伏感染艾滋病毒的细胞会抵抗抗病毒治疗。根除艾滋病毒讨论的主题是潜伏感染背后的生物学以及潜伏研究模型和刺激前病毒基因表达的药理学方法。关于艾滋病毒发病机制、治疗和根除前沿的 Keystone 研讨会将为学术界和工业界的众多科学家在艾滋病毒发病机制、药理学和根除领域自由交流思想和前沿成果创造一个环境。与同期举行的病毒进入、复制和发病机制细胞生物学会议的联合全体会议将突出共同感兴趣的主题，包括病毒进入和抑制机制，并将显着增加跨学科互动的机会。来自艾滋病毒复制和耐药领域的领导者将批判性地研究抗病毒治疗、新型抑制剂和重要的病毒与宿主相互作用的状况。从提交的摘要中选出的演讲者将填写有关艾滋病毒感染的药理学方法和细胞生物学的研讨会。 公共卫生相关性： 2012 年艾滋病毒发病机制、治疗和根除前沿重点研讨会将讨论与控制全球艾滋病毒/艾滋病流行相关的关键问题，包括根除患者体内持久性病毒库的可能性。考虑到联合国艾滋病规划署估计 2009 年有 180 万人死于艾滋病，这次会议非常及时且意义重大。同期举行的病毒进入、复制和发病机制的细胞生物学会议将大大增加跨学科互动的机会，该会议将与本次会议分享主题演讲和两场全体会议。